← Back to Search

PN-943 for Ulcerative Colitis

Phase 2
Waitlist Available
Research Sponsored by Protagonist Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 52
Awards & highlights

Study Summary

This trial is testing two doses of a new drug against placebo to see if it is safe and effective in treating moderate to severe ulcerative colitis.

Eligible Conditions
  • Ulcerative Colitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 52
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 52 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of subjects achieving clinical remission at Week 12 compared to placebo.
Secondary outcome measures
Comparison between PN-943 high-dose and low-dose individually to placebo.
Other outcome measures
Proportion of subjects achieving clinical remission at Week 52.

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: PN-943 450 mg BIDExperimental Treatment1 Intervention
Oral administration of PN-943 450 mg BID
Group II: PN-943 150 mg BIDExperimental Treatment1 Intervention
Oral administration of PN-943 150 mg BID
Group III: Placebo BIDPlacebo Group1 Intervention
Oral administration of matching placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PN-943
2020
Completed Phase 2
~170

Find a Location

Who is running the clinical trial?

Protagonist Therapeutics, Inc.Lead Sponsor
12 Previous Clinical Trials
790 Total Patients Enrolled
1 Trials studying Ulcerative Colitis
98 Patients Enrolled for Ulcerative Colitis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is PN-943 known to be safe and tolerable for patient consumption?

"With limited clinical evidence demonstrating PN-943's efficacy, a score of 2 was assigned to reflect its safety profile."

Answered by AI

Are investigators still accepting participants for this clinical experiment?

"According to records held on clinicaltrials.gov, this medical trial has closed recruitment and is no longer accepting applicants. The experiment was launched on August 5th 2020 and last updated February 16 2022; yet, 399 other studies remain open at present time."

Answered by AI

Can senior citizens aged 75+ participate in this trial?

"This clinical trial calls for participants older than 18 but younger than 75 years of age."

Answered by AI

Am I eligible to join this experiment?

"To meet the criteria for this clinical trial, ulcerative colitis patients aged 18 to 75 can apply. This medical experiment is set to accept a maxiumum of 150 participants."

Answered by AI

In what locales have the opportunities for this trial been made available?

"This medical trial is recruiting from 35 different clinics, including those in Garland, Miami and North Massapequa. To spare participants the hassle of unnecessary travel, they should opt for a clinic nearest to them if they wish to take part."

Answered by AI

Who else is applying?

What state do they live in?
Texas
How old are they?
18 - 65
What site did they apply to?
Protagonist Investigational Site
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)
2020. "PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04504383.
~36 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top